These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30709435)

  • 1. Novel pathway inhibitors for the treatment of chronic lymphocytic leukaemia.
    Molica S; Montserrat E
    Lancet Haematol; 2019 Feb; 6(2):e65-e66. PubMed ID: 30709435
    [No Abstract]   [Full Text] [Related]  

  • 2. Update on signal inhibitors in chronic lymphocytic leukemia.
    Boddu P; Jain N
    Clin Adv Hematol Oncol; 2018 Apr; 16(4):279-288. PubMed ID: 29742083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL-2 as a therapeutic target in chronic lymphocytic leukemia.
    Daniel C; Mato AR
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):210-218. PubMed ID: 28398276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
    Jacobs RW; Awan FT; Leslie LA; Usmani SZ; Ghosh N
    Expert Rev Hematol; 2016 Dec; 9(12):1177-1187. PubMed ID: 27791448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL.
    Kittai AS; Lunning M; Danilov AV
    Curr Hematol Malig Rep; 2019 Aug; 14(4):302-309. PubMed ID: 31049852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipids and Their Effects in Chronic Lymphocytic Leukemia.
    Friedman DR
    EBioMedicine; 2017 Feb; 15():2-3. PubMed ID: 27988133
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.
    Rossi D; Gerber B; Stüssi G
    Leuk Lymphoma; 2017 Jul; 58(7):1548-1560. PubMed ID: 27808579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?
    Frustaci AM; Montillo M; Picardi P; Mazzucchelli M; Cairoli R; Tedeschi A
    Expert Rev Hematol; 2016 Jul; 9(7):679-93. PubMed ID: 27253240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia.
    Burger JA
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):7-12. PubMed ID: 27168204
    [No Abstract]   [Full Text] [Related]  

  • 10. Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
    Patel K; Pagel JM
    Curr Hematol Malig Rep; 2019 Aug; 14(4):292-301. PubMed ID: 31203516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Chronic Lymphocytic Leukemia.
    Burger JA
    N Engl J Med; 2020 Jul; 383(5):460-473. PubMed ID: 32726532
    [No Abstract]   [Full Text] [Related]  

  • 12. The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia.
    Gianfelici V; Levato L; Molica S
    Curr Hematol Malig Rep; 2020 Aug; 15(4):343-349. PubMed ID: 32500413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
    Jain N; O'Brien S
    Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
    [No Abstract]   [Full Text] [Related]  

  • 15. Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.
    Rosenthal A
    Curr Hematol Malig Rep; 2017 Jun; 12(3):207-216. PubMed ID: 28439761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signal transduction inhibitors in chronic lymphocytic leukemia.
    Ma S; Rosen ST
    Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT-199 for chronic lymphocytic leukemia.
    Seymour J
    Clin Adv Hematol Oncol; 2014 Oct; 12(10):698-700. PubMed ID: 25658896
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.
    Puła A; Stawiski K; Braun M; Iskierka-Jażdżewska E; Robak T
    Leuk Lymphoma; 2018 May; 59(5):1084-1094. PubMed ID: 28891366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.
    Mato A; Jauhari S; Schuster SJ
    Am J Hematol; 2015 Jul; 90(7):657-64. PubMed ID: 25808792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis.
    Molica S; Giannarelli D; Mirabelli R; Levato L; Shanafelt TD
    Ann Hematol; 2018 Oct; 97(10):2005-2008. PubMed ID: 29740683
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.